Goldman Sachs’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-1,014,822
| Closed | -$48.7M | – | 4695 |
|
|
2020
Q1 | $48.7M | Buy |
1,014,822
+367,716
| +57% | +$17.7M | 0.02% | 791 |
|
|
2019
Q4 | $30.4M | Buy |
647,106
+83,387
| +15% | +$3.91M | 0.01% | 1333 |
|
|
2019
Q3 | $13.3M | Buy |
563,719
+348,385
| +162% | +$8.24M | ﹤0.01% | 1790 |
|
|
2019
Q2 | $6.48M | Sell |
215,334
-6,042
| -3% | -$182K | ﹤0.01% | 2161 |
|
|
2019
Q1 | $4.96M | Buy |
221,376
+21,667
| +11% | +$485K | ﹤0.01% | 2439 |
|
|
2018
Q4 | $3.64M | Buy |
199,709
+107,651
| +117% | +$1.96M | ﹤0.01% | 2521 |
|
|
2018
Q3 | $1.67M | Sell |
92,058
-41,735
| -31% | -$755K | ﹤0.01% | 2962 |
|
|
2018
Q2 | $1.33M | Buy |
133,793
+59,862
| +81% | +$596K | ﹤0.01% | 3062 |
|
|
2018
Q1 | $393K | Buy |
73,931
+44,994
| +155% | +$239K | ﹤0.01% | 3594 |
|
|
2017
Q4 | $246K | Buy |
28,937
+12,516
| +76% | +$106K | ﹤0.01% | 3737 |
|
|
2017
Q3 | $240K | Sell |
16,421
-56,682
| -78% | -$828K | ﹤0.01% | 3814 |
|
|
2017
Q2 | $1.37M | Buy |
73,103
+4,751
| +7% | +$89K | ﹤0.01% | 3000 |
|
|
2017
Q1 | $1.46M | Buy |
+68,352
| New | +$1.46M | ﹤0.01% | 2915 |
|